港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

东阳光药

45.800

-0.200-0.43%

成交量：25.73万

成交额：1,184.87万

市值：264.11亿

市盈率：22.01

高：46.520

开：46.500

低：45.600

收：46.000

52周最高：62.300

52周最低：44.000

股本：5.77亿

香港流通股本：1.13亿

量比：0.73

换手率：0.23%

股息：- -

股息率：- -

每股收益(LYR):2.081

净资产收益率：5.87%

总资产收益率：3.32%

市净率：2.85

市盈率(LYR):22.01

市销率: 6.50

数据加载中...

总览公司新闻公告

东阳光药(06887)自研乙肝小核酸新药国内获批临床

奥司他韦、达格列净等55种常用药集采拟中标结果出炉！多家上市药企公告拟中选

刚刚！红杉中国约21亿抄底拜耳王牌抗生素

MedTrend医趋势

新一批集采号召“理性报价”，仍有企业卷向低价，“流感药王”意外出局

东阳光药：自研慢性乙肝siRNA新药国内获批临床

聚焦：流感“抬头”！

最新！抗抑郁药TOP20洗牌，首仿、独家中成药疯涨，国药集团1类新药冲刺

东阳光药10月24日主力净流入71.7万元散户资金抛售

太惊人！49款国产1类新药来袭，恒瑞、东阳光药亮眼，正大天晴、华东......32个新药冲刺上市

MNC半年豪掷107亿美元，这个脂肪肝靶点终于爆了

东阳光药10月16日获主力加仓49.4万元

港股异动 | 东阳光药(06887)尾盘涨超4% 首仿盐酸芬戈莫德胶囊获国家药监局批准上市

招商研究 | 招闻天下1016

招商证券首次覆盖东阳光药(06887) 给予“强烈推荐”评级

关注三季度业绩预期和底部个股

向阳论医谈药

医药生物行业定期报告：FGF21：海外MNC抢滩的MASH明星靶点

近十年来首次下滑！城市实体药店3个超10亿品牌领跑，华润三九“称王”

东阳光药10月03日主力净流出107.8万元散户资金买入

东阳光药09月29日主力净流入73.3万元散户资金抛售

一张丙肝入场券！东阳光药如何从肝病赛道突围

医药研究社

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/06887/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06887\",,,,,undefined,":{"symbol":"06887","market":"HK","secType":"STK","nameCN":"东阳光药","latestPrice":45.8,"timestamp":1761898111065,"preClose":46,"halted":0,"volume":257330,"delay":0,"floatShares":112712832,"shares":576656047,"eps":2.080908,"marketStatus":"休市中","change":-0.2,"latestTime":"10-31 16:08:31","open":46.5,"high":46.52,"low":45.6,"amount":11848659,"amplitude":0.02,"askPrice":45.86,"askSize":300,"bidPrice":45.8,"bidSize":200,"shortable":0,"etf":0,"ttmEps":2.080908,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":7,"adr":0,"listingDate":1754496000000,"exchange":"SEHK","adjPreClose":46,"openAndCloseTimeList":[[1761874200000,1761883200000],[1761886800000,1761897600000]],"volumeRatio":0.7274971472935066,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06887\",,,,,undefined,":{"symbol":"06887","floatShares":112712832,"roa":"3.32%","roe":"5.87%","lyrEps":2.080908,"volumeRatio":0.7274971472935066,"shares":576656047,"dividePrice":0,"high":46.52,"amplitude":0.02,"preClose":46,"low":45.6,"week52Low":44,"pbRate":"2.85","psRate":"6.50","week52High":62.3,"institutionHeld":0,"latestPrice":45.8,"committee":-0.2,"eps":2.080908,"divideRate":0,"volume":257330,"delay":0,"ttmEps":2.080908,"open":46.5,"prevYearClose":60.24,"prevWeekClose":46.94,"prevMonthClose":45.8,"prevQuarterClose":49.6,"fiveDayClose":45.44,"twentyDayClose":49.6,"sixtyDayClose":60.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06887\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06887\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06887","date":"2025-10-30","current":22.009623,"percent":0.298246,"low":26.481481,"twenty":49.179195,"median":51.070574,"eighty":53.85491,"high":87.951651,"avg":51.616686,"sd":6.369744,"marketCap":26526178162},"quantilePoints":[{"date":"2025-08-08","current":87.951651,"twenty":38.775515,"median":57.216566,"eighty":75.657617,"marketCap":46410789719},{"date":"2025-08-15","current":53.544743,"twenty":50.854913,"median":50.910211,"eighty":53.207453,"marketCap":28212434399},{"date":"2025-08-22","current":46.053295,"twenty":48.528483,"median":50.885695,"eighty":53.358103,"marketCap":24189138855},{"date":"2025-08-29","current":48.593903,"twenty":46.280797,"median":49.970466,"eighty":52.516937,"marketCap":25645423745},{"date":"2025-09-05","current":50.421125,"twenty":47.199187,"median":49.797857,"eighty":51.668677,"marketCap":26583369945},{"date":"2025-09-12","current":49.629542,"twenty":47.419761,"median":49.970466,"eighty":51.668677,"marketCap":26213128024},{"date":"2025-09-19","current":54.62816,"twenty":48.205808,"median":50.411246,"eighty":53.54124,"marketCap":28832802350},{"date":"2025-09-26","current":53.850125,"twenty":48.404456,"median":50.853346,"eighty":54.601279,"marketCap":28348411270},{"date":"2025-10-03","current":53.088089,"twenty":48.593903,"median":50.910211,"eighty":54.493754,"marketCap":28013950763},{"date":"2025-10-10","current":52.114945,"twenty":48.663506,"median":51.880943,"eighty":54.471659,"marketCap":27460360958},{"date":"2025-10-17","current":51.235542,"twenty":48.675057,"median":51.667489,"eighty":54.265854,"marketCap":26975969878},{"date":"2025-10-24","current":51.392091,"twenty":48.841643,"median":51.235542,"eighty":53.929637,"marketCap":27068234846},{"date":"2025-10-30","current":50.28793,"twenty":49.179195,"median":51.070574,"eighty":53.85491,"marketCap":26526178162}],"updateTime":1761941574507},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06887\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579435666","title":"东阳光药(06887)自研乙肝小核酸新药国内获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2579435666","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579435666?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 13:35","pubTimestamp":1761888951,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国家药品监督管理局药品审评中心公开信息显示，东阳光药自主研发的siRNA疗法——HECN30227已获临床试验默示许可，批准开展慢性乙型肝炎适应症的临床试验。目前全球尚无乙肝siRNA药物获批上市。HECN30227是东阳光药自主研发并拥有全球知识产权的1类新药，也是公司基于小核酸技术平台开发的首款siRNA药物，可同时消除cccDNA和intDNA来源的乙肝表面抗原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"东阳光药(06887)自研乙肝小核酸新药国内获批临床","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"gpt_icon":0},{"id":"2579034539","title":"奥司他韦、达格列净等55种常用药集采拟中标结果出炉！多家上市药企公告拟中选","url":"https://stock-news.laohu8.com/highlight/detail?id=2579034539","media":"红星新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579034539?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 18:34","pubTimestamp":1761734040,"startTime":"0","endTime":"0","summary":"红星资本局10月29日消息，10月28日晚，国家医保局公布第十一批国家组织药品集中带量采购拟中选结果。竞争激烈远高于前十批集采抗流感等常用药中标结果出炉据国家医保局介绍，本次集采总体实现“稳临床、保质量、反内卷、防围标”预期目标。据红星资本局不完全统计，截至发稿，已有12家上市药企披露了产品拟中选公告。国药现代公告称，本次公司符合第十一批药品集中采购范围的产品共有7个，其中6个产品拟中选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029183506a47ba36d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029183506a47ba36d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","BK1197","02607","01093"],"gpt_icon":0},{"id":"2579190676","title":"刚刚！红杉中国约21亿抄底拜耳王牌抗生素","url":"https://stock-news.laohu8.com/highlight/detail?id=2579190676","media":"MedTrend医趋势","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579190676?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 18:32","pubTimestamp":1761733920,"startTime":"0","endTime":"0","summary":"截至发稿，红杉中国未对此传闻进行回应。其核心化合物专利原定于2012年6月到期，然而拜耳通过分案专利将保护期限延长至2014年9月，从而限制了仿制药的上市时间。截至目前，已通过仿制药一致性评价的莫西沙星在中国市场上已有数十款产品。根据协议，亿帆医药获得了这两款药物在中国大陆地区的独家市场推广权益。与以往不同的是，中国资本已崛起为过期专利药资产交易的关键参与者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029191317a47bb3d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029191317a47bb3d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1191","06887"],"gpt_icon":0},{"id":"2579245269","title":"新一批集采号召“理性报价”，仍有企业卷向低价，“流感药王”意外出局","url":"https://stock-news.laohu8.com/highlight/detail?id=2579245269","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579245269?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 16:01","pubTimestamp":1761724905,"startTime":"0","endTime":"0","summary":"在确认集采已中标后，深圳药企老板吴研匆匆赶往机场，开启下一趟跨国出差。回想这一次竞标历程，她多多少少在报价上觉得有些可惜。“我们的中标价，在我们可接受范围内，但如果当时我们的报价再提高0.6元，也可能有机会中标，这算是比较合理的价格，我们一度犹豫过。”吴研对第一财经记者说，本次集采，国家医保局试图引导企业理性报价，但在竞标过程中，还是感受到大家的‘卷’，普遍在报价上偏向保守。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510293548395194.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510293548395194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","06887"],"gpt_icon":0},{"id":"2579903498","title":"东阳光药：自研慢性乙肝siRNA新药国内获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2579903498","media":"药研界面","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579903498?lang=zh_cn&edition=fundamental","pubTime":"2025-10-29 12:54","pubTimestamp":1761713661,"startTime":"0","endTime":"0","summary":"据中国国家药品监督管理局药品审评中心公开信息显示，东阳光药siRNA疗法HECN30227慢性乙肝临床试验申请获批准。临床前数据表明，HECN30227具有泛基因型活性，可高效降低HBV表面抗原水平，对核苷类药物耐药株同样保持突出药效，体内外药效亦优于临床竞品。东阳光称基于对HBV清除机制的深刻了解，还正同步开发“siRNA+ASO+免疫调节剂”三联疗法，通过多靶点协同作用全面抑制乙肝病毒和表面抗原，并通过免疫重建开启乙肝“功能性治愈”新时代，为患者带来新希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029125607a47b0a68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251029125607a47b0a68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06887"],"gpt_icon":0},{"id":"2578579122","title":"聚焦：流感“抬头”！","url":"https://stock-news.laohu8.com/highlight/detail?id=2578579122","media":"科创日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578579122?lang=zh_cn&edition=fundamental","pubTime":"2025-10-25 08:00","pubTimestamp":1761350400,"startTime":"0","endTime":"0","summary":"目前，针对流感的治疗方式包括抗病毒治疗、对症支持治疗及其他辅助疗法。当前，流感疫苗已进入接种高峰期。其在年报中明确提及，四价流感疫苗降价对当期营收造成了直接影响。弗若斯特沙利文预测，2025年国内流感疫苗市场将重启增长，2032年规模有望达198亿元。目前，国家也正在以多元举措提升流感疫苗接种率，包括鼓励有条件地区政府采购，为部分重点人群免费接种；支持部分地区可用医保卡个人账户支付接种费用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025080137a6cccc2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251025080137a6cccc2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","BK1191"],"gpt_icon":0},{"id":"2578522108","title":"最新！抗抑郁药TOP20洗牌，首仿、独家中成药疯涨，国药集团1类新药冲刺","url":"https://stock-news.laohu8.com/highlight/detail?id=2578522108","media":"米内网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578522108?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 16:33","pubTimestamp":1761294838,"startTime":"0","endTime":"0","summary":"米内网数据显示，2025年上半年中国三大终端六大市场抗抑郁药销售额接近60亿元，集团“一哥”易主；化学药TOP20中石药首仿大涨540%，中成药TOP10中独家品种霸榜；抗抑郁国产新药研发推进，6款1类新药上市可期，涉及石药集团、东阳光药、国药集团等。2025H1中国三大终端六大市场抗抑郁药TOP20集团来源：米内网格局数据库在抗抑郁创新药研发方面，2021年以来，国内有3款中药1.1类新药及1款化药1类新药获批上市，为相关患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024164312a6cbab76&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024164312a6cbab76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","BK1191"],"gpt_icon":0},{"id":"2578757309","title":"东阳光药10月24日主力净流入71.7万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2578757309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578757309?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 16:15","pubTimestamp":1761293741,"startTime":"0","endTime":"0","summary":"10月24日, 东阳光药股价涨3.30%，报收46.94元，成交金额1205.1万元，换手率0.23%，振幅5.15%，量比1.11。东阳光药今日主力资金净流入71.7万元，上一交易日主力净流出0万元。该股近5个交易日上涨0.34%，主力资金累计净流入187.6万元；近20日主力资金累计净流入528.7万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024161907a4723e53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024161907a4723e53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06887"],"gpt_icon":0},{"id":"2576020534","title":"太惊人！49款国产1类新药来袭，恒瑞、东阳光药亮眼，正大天晴、华东......32个新药冲刺上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576020534","media":"米内网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576020534?lang=zh_cn&edition=fundamental","pubTime":"2025-10-19 08:04","pubTimestamp":1760832286,"startTime":"0","endTime":"0","summary":"据不完全统计，2025年至今已有49款国产1类新药获批上市，远超去年全年水平，恒瑞、东阳光药、复星等收获颇丰；32款1类新药有望于年内冲刺上市，抗肿瘤药为主力军，正大天晴、华东、人福等蓄势待发。32款1类新药冲刺上市，正大天晴、华东蓄势待发2025年四季度已至，多款创新药进入上市冲刺期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019081027a46722ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251019081027a46722ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06887","01276"],"gpt_icon":0},{"id":"2576772036","title":"MNC半年豪掷107亿美元，这个脂肪肝靶点终于爆了","url":"https://stock-news.laohu8.com/highlight/detail?id=2576772036","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576772036?lang=zh_cn&edition=fundamental","pubTime":"2025-10-17 07:28","pubTimestamp":1760657307,"startTime":"0","endTime":"0","summary":"FGF21，这个曾经默默无闻的靶点，正迅速成为代谢性疾病治疗领域的黄金赛道。2025年5月，GSK率先行动，以总额高达20亿美元的现金对价收购了Boston Pharmaceuticals的核心资产，FGF21类似物Efimosfermin alfa。随着FGF21资产不断被收购，业绩遭遇拐点的诺和诺德也终于坐不住了。2025年10月，诺和诺德宣布以最高52亿美元的价格收购美国生物技术公司Akero Therapeutics，获得其FGF21类似物Efruxifermin。MNC拼命在百亿级MASH市场中抢占先机，而这种布局也让FGF21靶点的竞争逐渐","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017073640a46401aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017073640a46401aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","IE00BZ08YS42.EUR","BK1515","BK1191","06887","IE00BZ08YR35.GBP","BK1589","IE00BZ08YT58.USD","01177"],"gpt_icon":0},{"id":"2575074404","title":"东阳光药10月16日获主力加仓49.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575074404","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575074404?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 16:15","pubTimestamp":1760602544,"startTime":"0","endTime":"0","summary":"10月16日, 东阳光药股价涨5.69%，报收48.30元，成交金额1738.7万元，换手率0.33%，振幅5.82%，量比1.00。东阳光药今日主力资金净流入49.4万元，上一交易日主力净流入84.7万元。|10月16日主力加仓幅度排名||#|股票简称|主力净额占比|#|立高控股|2.03%|#|大象控股集团|1.76%|#|创梦天地|1.63%|#|...|...|#347|东阳光药|0.01%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101616184797316bbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101616184797316bbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06887"],"gpt_icon":0},{"id":"2575790916","title":"港股异动 | 东阳光药(06887)尾盘涨超4% 首仿盐酸芬戈莫德胶囊获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575790916","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575790916?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 15:29","pubTimestamp":1760599748,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东阳光药尾盘涨超4%，截至发稿，涨4.38%，报47.7港元，成交额1498.24万港元。消息面上，10月11日，中国国家药品监督管理局官网公示，广东东阳光药业按化药注册分类申报的盐酸芬戈莫德胶囊获批上市，拿下国内首仿，也是该公司首款口服免疫抑制剂。招商证券发布研报称，东阳光药作为中国吸收合并及介绍上市第一股，通过吸收合并的方式构筑研产销一体化平台创新药企。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"港股异动 | 东阳光药(06887)尾盘涨超4% 首仿盐酸芬戈莫德胶囊获国家药监局批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","BK1191"],"gpt_icon":0},{"id":"2575639967","title":"招商研究 | 招闻天下1016","url":"https://stock-news.laohu8.com/highlight/detail?id=2575639967","media":"招商研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575639967?lang=zh_cn&edition=fundamental","pubTime":"2025-10-16 07:30","pubTimestamp":1760571021,"startTime":"0","endTime":"0","summary":"截至10月10日，R007下行20.0bp，DR007下行4.3bp，1年期国债收益率上行0.4bp，10年期国债收益率下行4.0bp，同业存单发行规模减少215.7亿元，6M同业存单利率上行，1M/3M同业存单利率下行。重要股东由净减持规模上升，公布的计划减持规模下降。VIX指数回升，海外市场风险偏好下降。商务部10月9日发布公告称，经国务院批准，决定对稀土相关技术等物项实施出口管制，未经许可，不得提供。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016073425a6bbf3d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251016073425a6bbf3d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0198837287.USD","LU1951198990.SGD","BK4141","LU1316542783.SGD","BK4529","LU0390134368.USD","LU1242518931.SGD","BK4588","LU0823421333.USD","LU2360106780.USD","GFS","BK4614","LU0979878070.USD","06887","LU2250418816.HKD","LU0056508442.USD","LU2458330243.SGD","LU1880398471.USD","LU2458330169.SGD","LU0823434583.USD","BK4534","LU1923623000.USD","LU0823421416.USD","LU1989764664.SGD","BK4512","IE00BMPRXN33.USD","BK4543","BK4551","LU2264538146.SGD","BK4605","LU0081259029.USD","BK4532","IE00B5949003.HKD","LU1064131342.USD","BK4023","BK4612","AI","BK4575","LU1861558580.USD","LU1951200564.SGD","LU0082616367.USD","BK4528","LU1852331112.SGD","LU0109392836.USD","LU0889565833.HKD","LU0719512351.SGD","AMD","BK4554","LU0127658192.USD","LU1303367103.USD","LU2054465674.USD"],"gpt_icon":1},{"id":"2575204845","title":"招商证券首次覆盖东阳光药(06887) 给予“强烈推荐”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2575204845","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575204845?lang=zh_cn&edition=fundamental","pubTime":"2025-10-15 16:39","pubTimestamp":1760517587,"startTime":"0","endTime":"0","summary":"基于对东阳光药研产销一体化平台价值、三大核心领域创新管线进展以及财务改善趋势的充分看好，招商证券首次覆盖便予东阳光药“强烈推荐”投资评级。在抗感染领域，东阳光药重点聚焦于乙肝功能性治愈这一全球性临床难题。目前东阳光药在临床前研究中均展现出优于国际同类在研产品的潜力，有望成为乙肝治疗领域的破局者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06887","06099"],"gpt_icon":0},{"id":"2575328207","title":"关注三季度业绩预期和底部个股","url":"https://stock-news.laohu8.com/highlight/detail?id=2575328207","media":"向阳论医谈药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575328207?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 15:17","pubTimestamp":1760339871,"startTime":"0","endTime":"0","summary":"截至目前，已获批用于MASH适应症治疗的药物仅包括Madrigal的THRβ激动剂resmetirom以及诺和诺德的GLP-1RA司美格鲁肽。2025年初以来至今，医药行业上涨21.87%，跑赢沪深300指数4.54个百分点，行业涨跌幅排名第12。此外，在EFX获批用于治疗MASH引起的代偿性肝硬化后，持有人有权获得总价值5亿美元的现金额外支付。本次收购最高总价达52亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013152416a6b6a573&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013152416a6b6a573&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06887","01276"],"gpt_icon":0},{"id":"2574913174","title":"医药生物行业定期报告：FGF21：海外MNC抢滩的MASH明星靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=2574913174","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574913174?lang=zh_cn&edition=fundamental","pubTime":"2025-10-12 00:00","pubTimestamp":1760198400,"startTime":"0","endTime":"0","summary":"FGF21：海外MNC 抢滩的MASH 明星靶点，国内有望映射: MASH 为全球范围内常见肝病，远期全球患者人数或达近5 亿人，药物市场或超300 亿美元。由于MASH 发病率高且病理过程复杂，因此全球范围内其在研管线及所覆盖的靶点众多，GLP-1、FXR、FGF-21 等靶点较为热门。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101216521897290645&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101216521897290645&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","06887","06978","02315","BK1161"],"gpt_icon":0},{"id":"2573846759","title":"近十年来首次下滑！城市实体药店3个超10亿品牌领跑，华润三九“称王”","url":"https://stock-news.laohu8.com/highlight/detail?id=2573846759","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573846759?lang=zh_cn&edition=fundamental","pubTime":"2025-10-06 08:19","pubTimestamp":1759709953,"startTime":"0","endTime":"0","summary":"精彩内容米内网数据显示，2025年上半年中国城市实体药店市场药品销售额超过1500亿元，同比下滑1.01%，其中化学药占比约51%，中成药占比约37%，生物药占比约12%。该市场以抗肿瘤药、慢病药为主，在化药及生物药TOP20品牌中，2个超10亿品牌领跑；在中成药TOP20品牌中，独家品种霸榜，华润医药亮了。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251006082411a4547ec5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251006082411a4547ec5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","BK1191"],"gpt_icon":0},{"id":"2572683474","title":"东阳光药10月03日主力净流出107.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2572683474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572683474?lang=zh_cn&edition=fundamental","pubTime":"2025-10-03 16:15","pubTimestamp":1759479343,"startTime":"0","endTime":"0","summary":"10月03日, 东阳光药股价跌1.10%，报收48.58元，成交金额993.4万元，换手率0.18%，振幅3.01%，量比0.57。东阳光药今日主力资金净流出107.8万元，上一交易日主力净流入198.8万元。该股近5个交易日下跌2.18%，主力资金累计净流出53.9万元；近20日主力资金累计净流出692.0万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003161900971e33e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003161900971e33e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","06887"],"gpt_icon":0},{"id":"2571639117","title":"东阳光药09月29日主力净流入73.3万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2571639117","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571639117?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 16:15","pubTimestamp":1759133753,"startTime":"0","endTime":"0","summary":"09月29日, 东阳光药股价涨0.24%，报收49.28元，成交金额2912.9万元，换手率0.53%，振幅2.56%，量比1.55。东阳光药今日主力资金净流入73.3万元，上一交易日主力净流出218.2万元。该股近5个交易日下跌1.04%，主力资金累计净流出153.6万元；近20日主力资金累计净流出626.1万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929162135a44bdc47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929162135a44bdc47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","BK1191"],"gpt_icon":0},{"id":"2570839288","title":"一张丙肝入场券！东阳光药如何从肝病赛道突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2570839288","media":"医药研究社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570839288?lang=zh_cn&edition=fundamental","pubTime":"2025-09-26 19:43","pubTimestamp":1758887005,"startTime":"0","endTime":"0","summary":"业内人士表示，当前活跃于国内丙肝市场的主要竞争者并不多，基本形成了吉利德、凯因科技和东阳光药的三强格局。而东阳光药出手便是一支百人级的肝病专线团队，在人员投入和专注度上的决心可见一斑。产品层面，东阳光药手握三款丙肝创新药，形成梯度产品矩阵。丙肝市场的集中发力，既是争夺当下份额，更是为深耕肝病领域建立“战略前哨”。至此，东阳光药战略目标已然清晰：剑锋所指，绝非丙肝一隅，而是整个中国肝病版图。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926221850a6a0542a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250926221850a6a0542a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","BK1191"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":70,"code":"91000000","status":"200"}]}}